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26, Basel CHObjective: This study aims to assess the odds of developing incident gout in association with the use of
postmenopausal estrogen-progestogen therapy, according to type, timing, duration, and route of administration of
estrogen-progestogen therapy.
Methods: We conducted a retrospective population-based case-control analysis using the United Kingdom–
based Clinical Practice Research Datalink. We identified women (aged 45 y or older) who had a first-time diagnosis
of gout recorded between 1990 and 2010. We matched one female control with each case on age, general practice,
calendar time, and years of active history in the database. We used multivariate conditional logistic regression to
calculate odds ratios (ORs) with 95% CIs (adjusted for confounders).
Results: The adjusted OR for gout with current use of oral formulations of opposed estrogens (estrogen-
progestogen) was 0.69 (95% CI, 0.56-0.86) compared with never use. Current use was associated with a decreased
OR for gout in women without renal failure (adjusted OR, 0.71; 95% CI, 0.57-0.87) and hypertension (adjusted OR,
0.62; 95% CI, 0.44-0.87) compared with never use. Tibolone was associated with a decreased OR for gout (adjusted
OR, 0.77; 95% CI, 0.63-0.95) compared with never use. Estrogens alone did not alter the OR for gout.
Conclusions: Current use of oral opposed estrogens, but not unopposed estrogens, is associated with a decreased
OR for incident gout in women without renal failure and is more pronounced in women with hypertension. Use of
tibolone is associated with a decreased OR for incident gout. The decreased OR for gout may be related to the
progestogen component rather than the estrogen component.
Key Words: Gout – Hormone therapy – Clinical Practice Research Datalink – Epidemiology – Estrogens
– Progestogens.
ty arthritis is a common painful inflammatory diagnosed in premenopausal women, but the incidence and
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arthritis with sudden onset, characterized by depo-
sition of monosodium urate crystals in affected
joints and surrounding tissue.1,2 Older age, male sex, hyper-
uricemia, obesity, and alcohol are important risk factors for
gout.3,4 Furthermore, arterial hypertension, renal failure, con-
gestive heart failure, and use of diuretics or antihypertensive
drugs have also been associated with increased risk of gout.5,6
The incidence of gout differs between men and women and
is strongly related to age in women.7,8 Gouty arthritis is rarely 2015 The North American Menopause Society.
ember 22, 2014; revised and accepted March 11, 2015.
asel Pharmacoepidemiology Unit, Division of Clinical
nd Epidemiology, Department of Pharmaceutical
versity of Basel, Basel, Switzerland; 2Hospital Pharmacy,
spital Basel, Basel, Switzerland; 3Division of General
icine, Bern University Hospital, Inselspital, Bern,
and 4Boston Collaborative Drug Surveillance Program,
rsity School of Public Health, Lexington, MA.
rt: This study was supported by an unconditional grant
let Foundation Switzerland, but the work was independ-
ed by the authors.
losure/conflicts of interest: None reported.
spondence to: Christoph R. Meier, PhD, MSc, Basel
emiology Unit, University Hospital Basel, Spitalstrasse
-4031, Switzerland. E-mail: Christoph.Meier@usb.chprevalence of gout increase after menopause. Several
authors demonstrated that urate levels—an important risk
factor for gout—substantially increase with age in women,
but not in men.10-12 This led to the notion that changes in
serum levels of female sex hormones after menopause may be
linked to increased urate levels and increased gout risk13-15
and that female sex hormones may protect against the devel-
opment of gouty arthritis.7,16-18 Indeed, investigations showed
that both estrogen and progestogen stimulate renal clearance
of uric acid and thereby decrease serum urate levels.11,12
Furthermore, postmenopausal hormone therapy (estrogen-
progestogen therapy [EPT]) was shown to also reduce serum
uric acid levels.19,20 Finally, in a study conducted by Hak
et al,9 postmenopausal EPT use was associated with a mod-
estly reduced gout risk, but they did not report on the dose,
duration, or route of administration of EPT, or the possible
differences between use of estrogens alone and use of opposed
estrogens (ie, estrogens plus progestogen).
EPT is licensed for relief of climacteric symptoms and for
prophylaxis against osteoporosis in perimenopausal and post-
menopausal women.21 Women with intact uteri usually take
combination estrogen-progestogen therapy, whereas women
who have had hysterectomy may receive unopposed
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estrogens.21 We conducted a large case-control analysis using inclusion of individuals with gout who, in fact, had another
BRUDERER ET ALa well-validated primary care database to explore the risk of
gout development in association with EPT use, with detailed
analyses of the type, timing, duration, and route of adminis-
tration of EPT.
METHODS
Data source
We derived data from the United Kingdom–based Clinical
Practice Research Datalink (CPRD), a large primary care
database established in 1987 that encompasses data from
some 450 general practices on some 8 million individuals
who are representative of the UK population22,23 with regard
to age, sex, geographic distribution, and annual turnover
rate.7,24,25 The CPRD holds information on participant dem-
ographics and characteristics, lifestyle variables (such as body
mass index [BMI], smoking status, and alcohol consumption),
symptoms, medical diagnoses, referrals to consultants, and
hospitalizations, which is recorded by general practitioners as
part of their daily routine when individuals consult them.
General practitioners generate drug prescriptions directly
with a computer using a coded drug dictionary. General
practitioners have been trained to record medical information
for research purposes using standard software and coding
systems. The database has been described in detail26,27 and
has been validated extensively.23,28-31 The CPRD has been the
source of numerous epidemiological studies published in
peer-reviewed journals, including research on gout.6-8,32,33
The Independent Scientific Advisory Committee for the
Medicines and Healthcare Products Regulatory Agency data-
base research approved the study.
Study population
Cases
Based on Read codes, we identified in the CPRD women
(aged 45 y or older) who had a first-time diagnosis of gout
recorded between 1990 and 2010. The date of the first
diagnosis of gout was referred to as the ‘‘index date.’’ Previous
studies of gout in the CPRD6-8,32,33 provided evidence that
diagnoses—albeit, in most cases, clinical diagnoses by gen-
eral practitioners—have high validity. In addition, we
reviewed a large sample of participant records to verify the
validity of inclusion and exclusion criteria, the incident
recording of the disease, and the validity of recording accord-
ing to treatment patterns and differential diagnoses around the
index date.
Exclusion criteria
We excluded all cases with less than 3 years of recorded
history before the index date to reduce the likelihood of
including prevalent gout cases. We further excluded all
women with a diagnosis of human immunodeficiency virus
or cancer (except nonmelanoma skin cancer) before the index
date and women with a diagnosis of hemochromatosis, septic
arthritis, rheumatoid arthritis, or osteoarthritis at any time in
participant records (to reduce the risk of misclassification; ie,
1336 Menopause, Vol. 22, No. 12, 2015Copyright @ 2015 The North American Menopause Societydisease with similar symptoms). The diagnosis of gout in the
CPRD has been validated in a previous study32 in which
similar case definitions were used.6-8,33
Control participants
We randomly identified from the CPRD a control group of
women without evidence of gout. We applied the same
exclusion criteria to controls as to cases. We matched (1:1)
controls to cases on age, general practice, number of years of
recorded history in the database, and index date.
Exposure
We identified EPT prescriptions before the index date and
classified exposed women into ‘‘current users’’ (last prescrip-
tion ending <90 d before the index date), ‘‘past users’’ (last
prescription ending 90 d before the index date), or ‘‘never
users.’’ We determined a cutoff of 90 days for current use
because this is the typical maximal length of a prescription in
the United Kingdom. We further classified EPT users accord-
ing to duration of use, with the number of EPT prescriptions
(1-9, 10-19, 20 prescriptions) before the index date used as
proxy for treatment duration. In addition, we distinguished
opposed (estrogen-progestogen) from unopposed (estrogen
only) EPT prescriptions and ran stratified analyses by route of
administration (oral, transdermal patch, vaginal, or others,
including gel, implant, nasal spray, and injection).
Covariates
We classified cases and controls according to their BMI
(unknown, 12.0-18.4, 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-
39.9, 40.0-44.9, 45.0 kg/m2), smoking status (nonsmoker,
current smoker, ex-smoker, unknown), alcohol consumption
(never/past, current [unknown, 1-9, 10-19, 20 units/wk],
unknown), and number of general practitioner visits within
the year immediately preceding the index date (0-2, 3-4, 5-9,
10). We assessed whether cases and controls had a recording
of hysterectomy, osteoporosis, hypertension, renal failure,
ischemic heart disease, congestive heart failure, stroke or
transient ischemic attack, diabetes mellitus, or dyslipidemia at
any time before the index date. Furthermore, we assessed the
association of use of antihypertensive drugs (b-blockers,
angiotensin-converting enzyme inhibitors, angiotensin recep-
tor blockers, calcium channel blockers, and organic nitrates),
statins, and low-dose acetylsalicylic acid within 180 days of
the index date with gout. A cutoff of 180 days was chosen to
better distinguish between current and past users because
these substances are prescribed for long-term use, and many
of these drugs are also available in packages containing more
than 90 tablets.
Sensitivity analysis
We conducted various sensitivity analyses. First, we
assessed the odds ratio (OR) for gout in association with
EPT use in the subset of cases (and their matched controls)
who were treated with nonsteroidal anti-inflammatory drugs,
 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.
Ccolchicine, and/or corticosteroids within 7 days of the index RESULTS
HORMONE THERAPY AND GOUTdate, or uricosuric/uricostatic drugs within 90 days of the
index date. This was performed to reduce the risk of mis-
classification (ie, to increase the likelihood of including valid
gout cases). In a second sensitivity analysis, we excluded
women with a history of renal failure, congestive heart failure,
or hypertension to eliminate residual confounding by these
important risk factors for gout. In a third sensitivity analysis,
we stratified the study population by the presence or absence
of these comorbidities. In a fourth sensitivity analysis, we
stratified the study population by hysterectomy status because
increased gout risk has previously been reported in younger
women who have had natural or surgical menopause.9 In a
fifth sensitivity analysis, we compared current EPT users to
the reference group of past EPT users to limit the risk of
potential confounding by indication. In a sixth sensitivity
analysis, we restricted the data to incident users of EPT by
excluding prevalent users to address potential prevalent user
bias; incident users were women without any prescriptions for
opposed or unopposed estrogens within the first year of their
registered history. In a seventh sensitivity analysis, we
assessed the ORs for gout (ever use vs never use) with
EPT stratified by route of administration. Finally, we assessed
the ORs for gout with EPT excluding tibolone because
tibolone is a synthetic steroid with properties different from
those of ‘‘simple’’ estrogens and progestogens.
Statistical analysis
We conducted multivariate conditional logistic regression
analyses to compare the exposure prevalence of EPT between
cases and controls. We present relative risk estimates as ORs
with 95% CIs. Two-sided P< 0.05 was considered statisti-
cally significant. We conducted statistical analysis using the
software program SAS version 9.3 (SAS Institute Inc, Cary,
NC).
In analyzing the odds for exposure, we adjusted for partici-
pant characteristics, comorbidities, or concomitant drug use in
multivariate analysis if these potential confounders were
predictor variables for gout known a priori from the literature:
BMI category (12.0-18.4, 18.5-24.9, 25.0-29.9, 30.0-34.9,
35.0-39.9, 40.0-44.9, 45.0 kg/m2), smoking status (non-
smoker, current smoker, ex-smoker, unknown), alcohol con-
sumption (never/past, current [unknown, 1-9, 10-19,
20 units/wk], unknown), and general practitioner visits
within the last year preceding the index date (0-2, 3-4, 5-9,
10) for all analyses. When we explored the association
between incident gout and baseline characteristics, including
lifestyle factors (alcohol consumption and smoking status)
and different comorbidities, we additionally adjusted our
analyses for hysterectomy status (yes/no) and previous
comorbidities such as hypertension (yes/no), congestive heart
failure (yes/no), ischemic heart disease (yes/no), and renal
failure (yes/no). For all other analyses, we simultaneously
adjusted for use of diuretic and antihypertensive drugs,
nitrates, statins, low-dose acetylsalicylic acid, and opposed
or unopposed estrogens.opyright @ 2015 The North American Menopause Society.The study population encompassed 13,489 incident gout
cases in women aged 45 years or older and the same number
of matched controls. The mean (SD) age at index date was 70
(12.3) years. All adjusted factors were associated with an
increased OR for incident gout in univariate analysis. Increas-
ing BMI was associated with a higher OR for gout, as was
current alcohol consumption in a dose-dependent manner.
Comorbidities known to be associated with increased risk of
gout, such as hypertension, renal failure, congestive heart
failure, and ischemic heart disease, were all associated with an
increased OR for incident gout (Table 1).
Current use of most antihypertensive drugs—except for
calcium channel blockers, which were associated with a
decreased OR for gout—was associated with an increased
OR for gout compared with never use of these drugs (Table 1).
Compared with never use, current use of opposed estrogens
(adjusted OR, 0.72; 95% CI, 0.59-0.88)—but not unopposed
estrogens (adjusted OR, 1.21; 95% CI, 0.98-1.48)—was
associated with a decreased OR for incident gout. ORs for
gout did not materially change with increasing number of
prescriptions among users of opposed or unopposed estro-
gens; however, an additional trend analysis using the number
of prescriptions as a continuous variable showed a statistically
significant P value of 0.0001 (Table 2).
Results from sensitivity analyses restricted to women with
pharmacologically treated gout or women without evidence of
renal failure, congestive heart failure, or hypertension did not
materially differ from the main analysis (data not shown).
When we stratified our analysis by renal failure, current use
of opposed estrogens was associated with a decreased OR for
gout in women without renal failure compared with never use
(adjusted OR, 0.71; 95% CI, 0.57-0.87), whereas no such
association was found in women with renal failure (adjusted
OR, 0.99; 95% CI, 0.53-1.86). In the analysis stratified by
hypertension, current use of opposed estrogens was associated
with a stronger protective effect (adjusted OR, 0.62; 95% CI,
0.44-0.87) on women with hypertension, whereas the associ-
ation was closer to null in cases and controls without hyperten-
sion (adjusted OR, 0.80; 95% CI, 0.63-1.02; Table 3). We
additionally ran a x2 test for interaction and found no inter-
action (P> 0.1) for renal failure, hypertension, and users of
opposed and unopposed estrogens. We could not stratify by the
presence or absence of congestive heart failure as there were too
few women with the disease. In the analysis stratified by
hysterectomy status (21.4% of cases and 17.3% of controls
had had hysterectomy), current use of opposed estrogens was
associated with a decreased OR in women who have not had
hysterectomy (OR, 0.71; 95% CI, 0.58-0.88), whereas no such
association was found in women with recorded hysterectomy
(data not shown). To address potential bias by indication, we
compared current use of opposed or unopposed estrogens with
past use of each and observed findings closely similar to those
for the main model (data not shown). In the analysis restricted to
current incident users of EPT compared with nonusers, the
results were closely similar to the main findings (data not
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TABLE 1. Baseline characteristics of women: gout cases (n¼ 13,489) and matched controls (n¼ 13,489)
Variable Cases, n (%) Controls, n (%) Crude OR (95% CI) Adjusted OR (95% CI)
Age groupa
45-49 y 786 (5.8) 786 (5.8) NA NA
50-54 y 984 (7.3) 988 (7.3) NA NA
55-59 y 1,264 (9.4) 1,256 (9.3) NA NA
60-64 y 1,442 (10.7) 1,440 (10.7) NA NA
65-69 y 1,304 (9.7) 1,319 (9.8) NA NA
70-74 y 1,527 (11.3) 1,525 (11.3) NA NA
75-79 y 1,600 (11.9) 1,609 (11.9) NA NA
80 y 4,582 (34.0) 4,566 (33.9) NA NA
BMI categoryb
12.0-18.4 kg/m2 165 (1.2) 303 (2.3) 0.80 (0.66-0.98) 0.78 (0.62-0.98)
18.5-24.9 kg/m2 2,871 (21.3) 4,386 (32.5) 1.00 (referent) 1.00 (referent)
25.0-29.9 kg/m2 3,772 (28.0) 3,300 (24.5) 1.83 (1.71-1.96) 1.58 (1.46-1.71)
30.0-34.9 kg/m2 2,422 (18.0) 1,276 (9.5) 3.23 (2.95-3.53) 2.50 (2.27-2.77)
35.0-39.9 kg/m2 1,054 (7.8) 390 (2.9) 4.51 (3.95-5.15) 3.20 (2.76-3.71)
40.0-44.9 kg/m2 410 (3.0) 97 (0.7) 7.30 (5.75-9.26) 4.78 (3.69-6.20)
45.0 kg/m2 214 (1.6) 41 (0.3) 8.95 (6.34-12.64) 5.17 (3.58-7.49)
Unknown 2,581 (19.1) 3,696 (27.4) 0.88 (0.82-0.96) 1.33 (1.19-1.49)
Smoking statusb
Nonsmoker 6,521 (48.3) 6,698 (49.7) 1.00 (referent) 1.00 (referent)
Current smoker 1,726 (12.8) 1,802 (13.4) 0.99 (0.91-1.07) 1.21 (1.11-1.33)
Ex-smoker 3,682 (27.3) 2,547 (18.9) 1.57 (1.48-1.68) 1.30 (1.20-1.40)
Unknown 1,560 (11.6) 2,442 (18.1) 0.54 (0.49-0.58) 1.15 (1.01-1.32)
Alcohol consumptionb,c
Never/past 3,016 (22.4) 2,750 (20.4) 1.00 (referent) 1.00 (referent)
Current, unknown units/wk 3,146 (23.3) 2,936 (21.8) 0.98 (0.91-1.06) 1.05 (0.96-1.15)
Current, 1-9 units/wk 3,238 (24.0) 3,160 (23.4) 0.95 (0.88-1.03) 1.13 (1.04-1.24)
Current, 10-19 units/wk 1,045 (7.8) 818 (6.1) 1.21 (1.08-1.35) 1.59 (1.39-1.81)
Current, 20 units/wk 501 (3.7) 261 (1.9) 1.80 (1.54-2.12) 2.03 (1.68-2.46)
Unknown 2,543 (18.9) 3,564 (26.4) 0.57 (0.53-0.62) 0.96 (0.85-1.09)
General practitioner visits within the last yearb
0-2 1,042 (7.7) 2,976 (22.1) 1.00 (referent) 1.00 (referent)
3-4 407 (3.0) 864 (6.4) 1.39 (1.20-1.61) 1.21 (1.03-1.41)
5-9 1,556 (11.5) 2,065 (15.3) 2.41 (2.17-2.68) 2.04 (1.81-2.29)
10 10,484 (77.7) 7,584 (56.2) 5.15 (4.71-5.64) 3.19 (2.87-3.53)
Comorbiditiesb
Hysterectomy 2,882 (21.4) 2,337 (17.3) 1.32 (1.24-1.40) 1.18 (1.09-1.27)
Osteoporosis 817 (6.1) 894 (6.6) 0.91 (0.82-1.00) 0.93 (0.83-1.05)
Hypertension 8,186 (60.7) 4,833 (35.8) 3.18 (3.00-3.36) 2.09 (1.95-2.23)
Diabetes mellitus 1,721 (12.8) 900 (6.7) 2.08 (1.91-2.27) 1.05 (0.94-1.16)
Dyslipidemia 2,408 (17.9) 1,559 (11.6) 1.78 (1.65-1.91) 1.07 (0.98-1.17)
Renal failure 4,689 (34.8) 2,583 (19.2) 4.44 (4.07-4.85) 2.39 (2.16-2.63)
Congestive heart failure 1,646 (12.2) 505 (3.7) 3.98 (3.56-4.45) 2.91 (2.57-3.31)
Ischemic heart disease 2,544 (18.9) 1,308 (9.7) 2.27 (2.11-2.45) 1.42 (1.30-1.56)
Stroke/TIA 1,292 (9.6) 905 (6.7) 1.51 (1.38-1.65) 1.14 (1.02-1.27)
Comedicationsd
ACE inhibitors 3,606 (26.7) 1,656 (12.3) 3.46 (3.21-3.72) 1.53 (1.40-1.68)
ARBs (excluding losartan) 1,009 (7.5) 415 (3.1) 2.90 (2.56-3.28) 1.24 (1.06-1.45)
Losartan 354 (2.6) 148 (1.1) 2.51 (2.07-3.05) 1.11 (0.69-1.77)
Loop diuretics 3,250 (24.1) 889 (6.6) 5.73 (5.23-6.29) 3.26 (2.92-3.63)
Thiazide diuretics 3,440 (25.5) 1,778 (13.2) 2.78 (2.59-2.98) 1.89 (1.73-2.06)
Potassium-sparing diuretics 557 (4.1) 117 (0.9) 5.31 (4.31-6.54) 2.33 (1.84-2.94)
b-Blockers 3,846 (28.5) 1,790 (13.3) 3.06 (2.86-3.28) 1.83 (1.68-1.99)
Calcium channel blockers 2,500 (18.5) 1,717 (12.7) 1.90 (1.77-2.05) 0.89 (0.82-0.98)
Nitrates 1,283 (9.5) 551 (4.1) 2.67 (2.40-2.97) 1.29 (1.13-1.47)
Statins 3,113 (23.1) 1,768 (13.1) 2.45 (2.27-2.64) 1.15 (1.04-1.26)
Low-dose acetylsalicylic acid 2,857 (21.2) 1,755 (13.0) 2.07 (1.92-2.22) 0.98 (0.89-1.07)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; NA, not applicable; OR, odds ratio; TIA, transient
ischemic attack.
aMatching variables: age, sex, general practice, history on database, and index date.
bAdjusted for BMI category (12.0-18.4, 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, 40.0-44.9, 45.0 kg/m2), smoking status (nonsmoker, current smoker,
ex-smoker, unknown), alcohol consumption (never/past, current [unknown, 1-9, 10-19, 20 units/wk], unknown), number of general practitioner visits
within the last year (0-2, 3-4, 5-9, 10), hysterectomy (yes/no), hypertension (yes/no), renal failure (yes/no), congestive heart failure (yes/no), and
ischemic heart disease (yes/no).
cOne unit equals 10 mL of pure ethanol (8 g of ethanol).
dAdjusted for BMI category (12.0-18.4, 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, 40.0-44.9, 45.0 kg/m2), smoking status (nonsmoker, current smoker,
ex-smoker, unknown), alcohol consumption (never/past, current [unknown, 1-9, 10-19, 20 units/wk], unknown), number of general practitioner visits
within the last year (0-2, 3-4, 5-9, 10), hysterectomy (yes/no), and prior prescription for ACE inhibitors (yes/no), ARBs excluding losartan (yes/no),
losartan (yes/no), loop diuretics (yes/no), thiazide diuretics (yes/no), potassium-sparing diuretics (yes/no), b-blockers (yes/no), calcium channel blockers
(yes/no), nitrates (yes/no), statins (yes/no), low-dose acetylsalicylic acid (yes/no), opposed estrogens (yes/no), and unopposed estrogens (yes/no).
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Cshown). Finally, in the analysis of users of EPT without tibolone Ever use of norethisterone acetate and estrogen, medrox-
TABLE 2. ORs for current use versus never use of hormone therapy in gout cases (n¼ 13,489) and matched controls (n¼ 13,489)
Hormone therapy Cases, n (%) Controls, n (%) Crude OR (95% CI) Adjusted OR (95% CI)a
Opposed estrogens
Never use 11,772 (87.3) 11,623 (86.2) 1.00 (referent) 1.00 (referent)
Current use
Overall 267 (2.0) 332 (2.5) 0.78 (0.66-0.92) 0.72 (0.59-0.88)
1-9 prescriptions 85 (0.6) 113 (0.8) 0.72 (0.54-0.97) 0.68 (0.49-0.95)
10-19 prescriptions 67 (0.5) 78 (0.6) 0.82 (0.59-1.15) 0.77 (0.52-1.14)
20 prescriptions 115 (0.9) 141 (1.1) 0.79 (0.62-1.02) 0.72 (0.53-0.97)
Past use
Overall 1,450 (10.8) 1,534 (11.4) 0.92 (0.84-1.00) 0.88 (0.79-0.97)
1-9 prescriptions 857 (6.4) 836 (6.2) 0.99 (0.90-1.10) 0.95 (0.83-1.07)
10-19 prescriptions 300 (2.2) 350 (2.6) 0.83 (0.71-0.98) 0.81 (0.67-0.98)
20 prescriptions 293 (2.2) 348 (2.6) 0.81 (0.69-0.96) 0.77 (0.63-0.94)
Unopposed estrogens
Never use 12,021 (89.1) 12,268 (91.0) 1.00 (referent) 1.00 (referent)
Current use
Overall 343 (2.5) 234 (1.7) 1.54 (1.30-1.83) 1.21 (0.98-1.48)
1-9 prescriptions 84 (0.6) 59 (0.4) 1.49 (1.06-2.09) 1.28 (0.87-1.89)
10-19 prescriptions 80 (0.6) 54 (0.4) 1.54 (1.08-2.18) 1.24 (0.83-1.87)
20 prescriptions 179 (1.3) 121 (0.9) 1.57 (1.23-1.99) 1.15 (0.87-1.53)
Past use
Overall 1,125 (8.3) 987 (7.3) 1.19 (1.08-1.30) 1.02 (0.91-1.14)
1-9 prescriptions 638 (4.7) 603 (4.5) 1.10 (0.98-1.23) 0.96 (0.84-1.11)
10-19 prescriptions 217 (1.6) 180 (1.3) 1.27 (1.04-1.55) 1.16 (0.91-1.48)
20 prescriptions 270 (2.0) 204 (1.5) 1.38 (1.15-1.67) 1.09 (0.86-1.37)
OR, odds ratio.
aAdjusted for body mass index category (12.0-18.4, 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, 40.0-44.9, 45.0 kg/m2), smoking status (nonsmoker,
current smoker, ex-smoker, unknown), alcohol consumption (never/past, current [unknown, 1-9, 10-19, 20 units/wk], unknown), number of general
practitioner visits within the last year (0-2, 3-4, 5-9, 10), and prior prescription for angiotensin-converting enzyme inhibitors (yes/no), angiotensin
receptor blockers excluding losartan (yes/no), losartan (yes/no), loop diuretics (yes/no), thiazide diuretics (yes/no), potassium-sparing diuretics (yes/no), b-
blockers (yes/no), calcium channel blockers (yes/no), nitrates (yes/no), statins (yes/no), low-dose acetylsalicylic acid (yes/no), opposed estrogens (yes/no),
and unopposed estrogens (yes/no).
HORMONE THERAPY AND GOUTcompared with nonusers, the results were closely similar to the
main findings (data not shown).opyright @ 2015 The North American Menopause Society.
TABLE 3. ORs for hormone therapy use, stratified by ren
and matched contro
With comorbidity before the index date
Cases,
n (%)
Controls,
n (%)
Crude OR
(95% CI)
Adjusted
(95% C
Renal failure 4,689 (34.8) 2,583 (19.2)
Opposed estrogens
Nonuse 4,252 (31.5) 2,328 (17.3) 1.00 (referent) 1.00 (refer
Current use 40 (0.3) 21 (0.2) 0.91 (0.52-1.60) 0.99 (0.53-
Past use 397 (2.9) 234 (1.7) 0.82 (0.68-0.98) 0.82 (0.66-
Unopposed estrogens
Nonuse 4,250 (31.5) 2,363 (17.5) 1.00 (referent) 1.00 (refer
Current use 46 (0.3) 18 (0.1) 1.05 (0.59-1.87) 1.30 (0.67-
Past use 393 (2.9) 202 (1.5) 1.08 (0.89-1.31) 1.05 (0.84-
Hypertension 8,186 (60.7) 4,833 (35.8)
Opposed estrogens
Nonuse 7,290 (54.0) 4,267 (31.6) 1.00 (referent) 1.00 (refer
Current use 104 (0.8) 79 (0.6) 0.65 (0.48-0.88) 0.62 (0.44-
Past use 792 (5.9) 487 (3.6) 0.90 (0.79-1.02) 0.77 (0.66-
Unopposed estrogens
Nonuse 7,317 (54.2) 4,391 (32.6) 1.00 (referent) 1.00 (refer
Current use 182 (1.4) 73 (0.5) 1.38 (1.03-1.84) 1.17 (0.84-
Past use 687 (5.1) 369 (2.7) 1.15 (1.00-1.32) 0.95 (0.81-
OR, odds ratio.
aAdjusted for body mass index category (12.0-18.4, 18.5-24.9, 25.0-29.9, 30.0-3
current smoker, ex-smoker, unknown), alcohol consumption (never/past, current
practitioner visits within the last year (0-2, 3-4, 5-9, 10), and prior prescriptio
receptor blockers excluding losartan (yes/no), losartan (yes/no), loop diuretics (y
b-blockers (yes/no), calcium channel blockers (yes/no), nitrates (yes/no), statins
(yes/no), and unopposed estrogens (yes/no).yprogesterone acetate and estrogen, and tibolone was associ-
ated with a decreased OR for incident gout compared with Unauthorized reproduction of this article is prohibited.
al failure and hypertension, in gout cases (n¼ 13,489)
ls (n¼ 13,489)
Without comorbidity before the index date
OR
I)a
Cases,
n (%)
Controls,
n (%)
Crude OR
(95% CI)
Adjusted OR
(95% CI)a
8,800 (65.2) 10,906 (80.9)
ent) 7,520 (55.8) 9,295 (68.9) 1.00 (referent) 1.00 (referent)
1.86) 227 (1.7) 311 (2.3) 0.80 (0.66-0.96) 0.71 (0.57-0.87)
1.02) 1,053 (7.8) 1,300 (9.6) 0.97 (0.88-1.07) 0.90 (0.80-1.01)
ent) 7,771 (57.6) 9,905 (73.4) 1.00 (referent) 1.00 (referent)
2.52) 297 (2.2) 216 (1.6) 1.68 (1.40-2.03) 1.23 (0.99-1.52)
1.30) 732 (5.4) 785 (5.8) 1.25 (1.12-1.40) 1.04 (0.91-1.19)
5,303 (39.3) 8,656 (64.2)
ent) 4,482 (33.2) 7,356 (54.5) 1.00 (referent) 1.00 (referent)
0.87) 163 (1.2) 253 (1.9) 0.92 (0.74-1.13) 0.80 (0.63-1.02)
0.89) 658 (4.9) 1,047 (7.8) 1.00 (0.89-1.12) 1.00 (0.88-1.14)
ent) 4,704 (34.9) 7,877 (58.4) 1.00 (referent) 1.00 (referent)
1.61) 161 (1.2) 161 (1.2) 1.55 (1.23-1.96) 1.25 (0.96-1.62)
1.12) 438 (3.3) 618 (4.6) 1.23 (1.07-1.41) 1.14 (0.98-1.33)
4.9, 35.0-39.9, 40.0-44.9, 45.0 kg/m2), smoking status (nonsmoker,
[unknown, 1-9, 10-19, 20 units/wk], unknown), number of general
n for angiotensin-converting enzyme inhibitors (yes/no), angiotensin
es/no), thiazide diuretics (yes/no), potassium-sparing diuretics (yes/no),
(yes/no), low-dose acetylsalicylic acid (yes/no), opposed estrogens
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never use of these drugs (Table 4). Current use of oral opposed OR for gout among current users of opposed estrogens was
TABLE 4. ORs for hormone therapy use, stratified by progesterone component (single substance), in gout cases (n¼ 13,489)
and matched controls (n¼ 13,489)
Hormone therapy Cases, n (%) Controls, n (%) Crude OR (95% CI) Adjusted OR (95% CI)a
Opposed estrogens
Nonuse 11,807 (87.5) 11,652 (86.4) 1.00 (referent) 1.00 (referent)
Ever use, by substance
Dydrogesterone and estrogen 65 (0.5) 70 (0.5) 0.90 (0.63-1.27) 0.97 (0.63-1.48)
Levonorgestrel and estrogen 87 (0.6) 95 (0.7) 0.89 (0.66-1.19) 0.77 (0.55-1.10)
Norethisterone and estrogen 607 (4.5) 671 (5.0) 0.88 (0.78-0.99) 0.81 (0.70-0.94)
Medroxyprogesterone acetate and estrogen 199 (1.5) 251 (1.9) 0.77 (0.63-0.93) 0.69 (0.54-0.87)
Norgestrel and estrogen 439 (3.3) 429 (3.2) 0.99 (0.86-1.14) 0.98 (0.83-1.17)
Raloxifene 35 (0.3) 39 (0.3) 0.88 (0.55-1.39) 1.23 (0.69-2.17)
Tibolone 250 (1.9) 282 (2.1) 0.86 (0.72-1.02) 0.77 (0.63-0.95)
OR, odds ratio.
aAdjusted for body mass index category (12.0-18.4, 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, 40.0-44.9, 45.0 kg/m2), smoking status (nonsmoker,
current smoker, ex-smoker, unknown), alcohol consumption (never/past, current [unknown, 1-9, 10-19, 20 units/wk], unknown), number of general
practitioner visits within the last year (0-2, 3-4, 5-9, 10), and prior prescription for angiotensin-converting enzyme inhibitors (yes/no), angiotensin
receptor blockers excluding losartan (yes/no), losartan (yes/no), loop diuretics (yes/no), thiazide diuretics (yes/no), potassium-sparing diuretics (yes/no),
b-blockers (yes/no), calcium channel blockers (yes/no), nitrates (yes/no), statins (yes/no), low-dose acetylsalicylic acid (yes/no), and unopposed estrogens
(yes/no).
BRUDERER ET ALestrogens, but not of other routes of administration, was
associated with a significantly decreased OR for incident
gout (adjusted OR, 0.69; 95% CI, 0.56-0.86). Further results
are displayed in Table 5.
DISCUSSION
In this large population-based case-control study, current
use of opposed estrogens—but not unopposed estrogens—
was associated with a decreased OR for incident gout
(adjusted OR, 0.72; 95% CI, 0.59-0.88). The OR reduction
was not dependent on the duration of EPT use. The decreasedCopyright @ 2015 The North American Menopause Society
TABLE 5. ORs for current use versus never use of hormone therapy, str
and matched contro
Hormone therapy Cases, n (%) Controls, n (%)
Opposed estrogens
Never use 11,772 (87.3) 11,623 (86.2)
Current use, by route of administration
Patch 24 (0.2) 28 (0.2)
Oral 236 (1.8) 298 (2.2)
Past use, by route of administration
Patch 109 (0.8) 111 (0.8)
Oral 1,292 (9.6) 1,378 (10.2)
Others 56 (0.4) 51 (0.4)
Unopposed estrogens
Never use 12,021 (89.1) 12,268 (91.0)
Current use, by route of administration
Patch 73 (0.5) 62 (0.5)
Oral 216 (1.6) 124 (0.9)
Vaginal 37 (0.3) 34 (0.3)
Others 17 (0.1) 14 (0.1)
Past use, by route of administration
Patch 320 (2.4) 267 (2.0)
Oral 536 (4.0) 423 (3.1)
Vaginal 189 (1.4) 243 (1.8)
Others 80 (0.6) 54 (0.4)
OR, odds ratio.
aAdjusted for body mass index category (12.0-18.4, 18.5-24.9, 25.0-29.9, 30.0-3
current smoker, ex-smoker, unknown), alcohol consumption (never/past, current [u
practitioner visits within the last year (0-2, 3-4, 5-9, 10), and prior prescription f
blockers excluding losartan (yes/no), losartan (yes/no), loop diuretics (yes/no), thia
(yes/no), calcium channel blockers (yes/no), nitrates (yes/no), statins (yes/no), low
1340 Menopause, Vol. 22, No. 12, 2015only observed in women without renal failure. Of interest, when
we stratified by arterial hypertension (another comorbidity that
has been associated with an increased OR for gout in this study
and in other studies),5,6 the observed OR reduction was more
pronounced in cases and controls with recorded arterial hyper-
tension. Again, no such OR reduction was seen in users of
unopposed estrogens. When we stratified by hysterectomy
status, a protective effect of opposed estrogens was observed
in women who have not had hysterectomy, whereas no associ-
ation was observed in users of unopposed estrogens. When we
stratified opposed estrogens by progestogen component, only. Unauthorized reproduction of this article is prohibited.
atified by route of administration, in incident gout cases (n¼ 13,489)
ls (n¼ 13,489)
Crude OR (95% CI) Adjusted OR (95% CI)a
1.00 (referent) 1.00 (referent)
0.82 (0.47-1.43) 0.95 (0.50-1.82)
0.77 (0.64-0.91) 0.69 (0.56-0.86)
0.95 (0.73-1.24) 0.83 (0.60-1.16)
0.91 (0.83-0.99) 0.88 (0.79-0.98)
1.07 (0.73-1.57) 1.03 (0.64-1.65)
1.00 (referent) 1.00 (referent)
1.27 (0.91-1.79) 1.02 (0.68-1.53)
1.85 (1.47-2.33) 1.37 (1.05-1.78)
1.10 (0.69-1.75) 0.87 (0.49-1.53)
1.27 (0.62-2.57) 1.39 (0.63-3.10)
1.25 (1.06-1.48) 0.98 (0.79-1.20)
1.32 (1.15-1.50) 1.17 (0.99-1.37)
0.80 (0.66-0.97) 0.75 (0.59-0.95)
1.56 (1.10-2.21) 1.32 (0.86-2.02)
4.9, 35.0-39.9, 40.0-44.9, 45.0 kg/m2), smoking status (nonsmoker,
nknown, 1-9, 10-19, 20 units/wk], unknown), number of general
or angiotensin-converting enzyme inhibitors (yes/no), angiotensin receptor
zide diuretics (yes/no), potassium-sparing diuretics (yes/no), b-blockers
-dose acetylsalicylic acid (yes/no), and unopposed estrogens (yes/no).
 2015 The North American Menopause Society
Cnorethisterone acetate and estrogen, and medroxyprogesterone exposure was prospectively entered in the CPRD in the
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HORMONE THERAPY AND GOUTacetate and estrogen were associated with a decreased OR for
incident gout. Tibolone—a synthetic steroid hormone acting as
a selective tissue estrogenic activity regulator acting as an
estrogen receptor agonist34 whose metabolites have estrogenic,
androgenic, and progestogenic properties35—was also associ-
ated with a decreased OR for gout. The effect of tibolone might
be explained by its progestogenic component. When we strati-
fied by route of administration, current use of oral opposed
estrogens was associated with a significantly decreased OR for
incident gout, whereas transdermal patches were not associated
with an altered OR. Taken together, our results suggest that the
progestogen component in opposed estrogens may explain the
observed relative decrease in the OR for gout in association
with the use of opposed estrogens, an OR reduction that was
only observed in the absence of renal failure and was more
pronounced in the presence of diagnosed arterial hypertension,
suggesting effect modification by these parameters.
To our best knowledge, the study conducted by Hak et al9 is,
to date, the only study to have explored the association between
EPT use and risk of incident gout. They found a slightly
decreased risk of gout in postmenopausal users of EPT (relative
risk, 0.82; 95% CI, 0.70-0.96) compared with nonusers of EPT.
However, they did not report findings on the type (opposed vs
unopposed), duration, or route of administration of EPT.9
Serum uric acid levels increase in older postmenopausal
women,10 and decreased serum uric acid levels have been
observed in users of EPT compared with postmenopausal
women not using EPT.10,19,20 In line with these observations,
investigators showed that use of estrogens and progestogen
leads to increased renal clearance of urate and therefore
decreased serum urate levels.11,12,20 However, the underlying
causes of these age and sex differences remain unclear, and
the number of participants analyzed was small.11,12,20 In our
study, use of opposed estrogens was not associated with a
decreased OR for gout in women with renal failure (ie, a
participant subgroup with reduced renal uric acid excretion).
However, because use of unopposed estrogens was not associ-
ated with an altered OR for gout in either the main analyses or
the stratified analyses, these findings do not support the
hypothesis that altered renal uric acid handling alone explains
our findings; this may be explained by the uricosuric effect of
progestogens, but not of estrogens alone. Furthermore, hy-
pertension also had an influence on the observed OR
reduction seen for opposed estrogens.
Our large population-based study has several strengths. We
were in a position to study a large number of cases with incident
gout in a well-established primary care database.23,28-31 Further-
more, we were able to analyze opposed and unopposed estro-
gens separately and to explore the OR for gout in association
with duration and route of administration of EPT. We were
able to run various sensitivity analyses to address potential
biases. We further adjusted our analyses for important poten-
tial confounders such as BMI, smoking status, alcohol con-
sumption, renal failure, hypertension, and concomitant drug
therapies. Because information on diseases and drugopyright @ 2015 The North American Menopause Society.absence of any study hypothesis, recall bias is not an issue.
Some limitations of our study have to be acknowledged.
Misclassification of some gout cases may have occurred,
although a previous study has shown that gout diagnoses
are recorded in the CPRD with high validity.32 To minimize
misclassification, we excluded women with recorded diag-
noses of other rheumatic disorders at any time within their
history, and we further excluded all women with less than 3
years of recorded history in the database before the index date
to reduce the risk of including prevalent rather than incident
gout cases. We were not in a position to assess menopause
because menopause status was not consistently recorded by
general practitioners. However, EPT is prescribed mostly to
postmenopausal women for symptomatic relief, usually as
combined EPT in women with intact uterus.21 The analysis
stratified by hysterectomy status was consistent with results
from the main analysis; we therefore assume that our study
population is representative of postmenopausal women.
Because the numbers of cases and controls among hormone
therapy users in the stratified analyses were rather small for
some agents, results have to be interpreted with caution. In
addition, we were not able to adjust for all known potential
risk factors for gout because, for example, dietary habits or
physical activity1,3 are not routinely recorded in the CPRD.
However, we adjusted for BMI, a factor that is related to
physical activity and dietary habits. Finally, we could not
address potential confounding by socioeconomic status, but
we partially controlled for this parameter by matching cases
and controls on general practitioner because women from the
same neighborhood tend to see the same general practitioner.
CONCLUSIONS
This large observational study provides evidence that current
oral use of opposed estrogens is associated with a decreased OR
for incident gout. OR reduction is only observed in women with
normal renal function and is more pronounced in women with
hypertension. Current use of oral unopposed estrogens is not
associated with a decreased OR for gout in postmenopausal
women. Thus, these findings provide evidence that the reduced
OR for gout seen with EPT use may be related to the proges-
togen component rather than the estrogen component.technical support.
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